Diabetic ketoacidosis associated with aripiprazole

Pharmacotherapy

Volumn 28, Issue 9, 2008, Pages 1198-1202

  Makhzoumi, Zaineb H ^a   McLean, Leon P ^b   Lee, Jefferson H ^a   Ibe, Ada I ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Adverse drug reaction; Antipsychotic; Aripiprazole; Diabetes; Diabetic ketoacidosis; Psychiatry

Indexed keywords

ARIPIPRAZOLE; ATORVASTATIN; BENZATROPINE; FLUPHENAZINE; INSULIN; VALPROIC ACID;

ADULT; AKATHISIA; ANAMNESIS; ARTICLE; BEDTIME DOSAGE; CASE REPORT; DIABETIC KETOACIDOSIS; DRUG DOSE INCREASE; HUMAN; HYDRATION; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LABORATORY TEST; MALE; PHYSICAL EXAMINATION; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; DIABETIC KETOACIDOSIS; FLUID THERAPY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES;

EID: 51849094879     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.9.1198     Document Type: Article

References (15)

1. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004;10:317-36.
2. Swainston HT, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-36.
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601.
4. Tahir R. Metabolic effects of atypical antipsychotics. US Pharm 2007;32(11):HS3-14.
5. Boehm G, Racoosin JA, Laughren TP, Katz R. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004;27:2088-9.
6. Reddymasu S, Bahta E, Levine S, Manas K, Slay LE. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. J Pancreas 2006;7:303-5.
7. Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005;22:1440-3.
8. Foster DW, McGarry JD. The metabolic derangements and treatment of diabetic ketoacidosis. N Engl J Med 1983;309:159-69.
9. Wachtel TJ. The diabetic hyperosmolar state. Clin Geriatr Med 1990;6:797-806.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, et al. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med 1991;6:495-502.
12. Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972;51(2):73-94.
13. United States Food and Drug Administration. MedWatch. 2004 safety alert: Zyprexa (olanzapine), March 2004. Available from http://www.fda.gov/ medwatch/SAFETY/2004/safety04.htm#zyprexa. Accessed March 24, 2008.
14. United States Food and Drug Administration. Aripiprazole patient information sheet, September 2006. Available from http://www.fda.gov/cder/drug/ InfoSheets/patient/aripiprazolePlS.pdf. Accessed March 24, 2008.
15. Noel JM. ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders. Am J Health-Syst Pharm 2007;64:863-76.